Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,725
  • Shares Outstanding, K 26,810
  • Annual Sales, $ 9,940 K
  • Annual Income, $ -164,570 K
  • EBIT $ -127 M
  • EBITDA $ -124 M
  • 60-Month Beta 1.59
  • Price/Sales 6.80
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 474.72% ( -17.22%)
  • Historical Volatility 100.72%
  • IV Percentile 98%
  • IV Rank 94.66%
  • IV High 501.16% on 10/30/24
  • IV Low 5.84% on 11/14/23
  • Put/Call Vol Ratio 1.01
  • Today's Volume 257
  • Volume Avg (30-Day) 470
  • Put/Call OI Ratio 7.79
  • Today's Open Interest 22,916
  • Open Int (30-Day) 17,761

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.80
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -0.85
  • Prior Year -1.19
  • Growth Rate Est. (year over year) +32.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.82 +33.52%
on 10/16/24
2.77 -12.27%
on 10/29/24
+0.47 (+23.98%)
since 10/04/24
3-Month
1.43 +69.93%
on 09/10/24
5.53 -56.06%
on 08/06/24
-3.04 (-55.58%)
since 08/02/24
52-Week
1.43 +69.93%
on 09/10/24
8.17 -70.26%
on 01/02/24
-0.05 (-2.02%)
since 11/03/23

Most Recent Stories

More News
S&P Futures Tick Higher Ahead of Key U.S. PPI Data, Home Depot Earnings on Tap

September S&P 500 E-Mini futures (ESU24) are trending up +0.11% this morning as investors awaited crucial U.S. producer inflation data, comments from a Federal Reserve official, and an earnings report...

ESU24 : 5,699.99s (-0.31%)
KEY : 17.04 (-0.87%)
MNDY : 295.78 (-1.26%)
SBUX : 97.03 (-1.86%)
RILY : 4.92 (-13.68%)
HD : 395.57 (+0.76%)
TECN.Z.EB : 220.600 (-0.27%)
FNOX.S.DX : 69.300 (+7.28%)
CXAI : 1.3500 (-3.57%)
SYRS : 2.43 (+7.28%)
RUM : 5.77 (-0.52%)
DELL : 129.85 (-0.78%)
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 2.43 (+7.28%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 2.43 (+7.28%)
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for...

SYRS : 2.43 (+7.28%)
Syros to Participate in Upcoming Investor Conferences in March

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive...

SYRS : 2.43 (+7.28%)
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 2.43 (+7.28%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 2.43 (+7.28%)
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United...

SYRS : 2.43 (+7.28%)
Syros Announces Clinical Updates and 2023 Strategic Priorities

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and...

SYRS : 2.43 (+7.28%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200...

SYRS : 2.43 (+7.28%)

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients...

See More

Key Turning Points

3rd Resistance Point 2.88
2nd Resistance Point 2.70
1st Resistance Point 2.57
Last Price 2.43
1st Support Level 2.26
2nd Support Level 2.08
3rd Support Level 1.95

See More

52-Week High 8.17
Fibonacci 61.8% 5.60
Fibonacci 50% 4.80
Fibonacci 38.2% 4.00
Last Price 2.43
52-Week Low 1.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar